The global clinical immunodiagnostics market was valued at USD 4.8 Billion in 2022 and is expected to reach USD 8.4 Billion by 2033. The immunoassay kits & reagents segment with a market share of more than 67.0% has topped the global market within the product category and is expected to grow at a CAGR of close to 5.4% over the forecast period (2023 to 2033).
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Clinical Immunodiagnostics Market Value 2022 | USD 4.8 Billion |
| Market Value 2023 | USD 5.0 Billion |
| Market Value 2033 | USD 8.4 Billion |
| CAGR 2023 to 2033 | 5.4% |
| Market Share of Top 5 Countries (2022) | 58.0% |
Clinical immunodiagnostics refers to the diagnostic tests and technologies that utilize immunodiagnostic techniques to detect and measure specific antibodies, antigens, or immune markers in patient samples. Immunodiagnostics involves the interaction between antigens and antibodies, forming an immune complex that is then detected and quantified to provide diagnostic information.
Clinical immunodiagnostics plays a crucial role in diagnosing various diseases and conditions, monitoring treatment efficacy, and assessing immune system function. These tests are commonly used in clinical laboratories, hospitals, and research institutions to identify and measure immune markers associated with infectious diseases, autoimmune disorders, allergies, cancer, and other medical conditions.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The global market for clinical immunodiagnostics was around 3.7% of the overall USD 128.2 Billion of the global in vitro diagnostics market in 2022.
The market has experienced significant growth over the years. The increasing prevalence of infectious diseases, autoimmune disorders, and cancer, coupled with advancements in immunodiagnostic technologies, has contributed to the expansion of the market.
The introduction of novel assays improved the sensitivity and specificity of tests, and the adoption of automated platforms has played a key role in the historic growth of the clinical immunodiagnostics market. The global burden of infectious diseases, chronic diseases, and conditions related to the immune system is expected to rise continuously in the coming years.
This will drive the demand for accurate and reliable diagnostic tests, including clinical immunodiagnostics. Also, the need for early disease detection, personalized medicine, and effective monitoring of treatment outcomes will fuel market growth.
Ongoing advancements in immunodiagnostic technologies, such as multiplex assays, high-sensitivity detection methods, and point-of-care testing, are expected to enhance the performance and accessibility of clinical immunodiagnostics. These technological advancements will enable rapid and accurate diagnosis, resulting in increased adoption and market growth.
Owed to the above factors, the global market is projected to grow at a CAGR of 5.4% in the forecasted period.
Clinical Immunodiagnostics are essential in personalized medicine because it helps in facilitating the diagnosis and monitoring of diseases at an individual level. As the demand for personalized treatment options continues to rise, clinical immunodiagnostics product manufacturers have an opportunity to develop innovative assays that enable targeted therapies and precision medicine.
The integration of clinical immunodiagnostics with therapeutics, particularly in oncology, presents opportunities for manufacturers. As targeted therapies become more prevalent, the demand for companion diagnostics is likely to grow. Developing tests that identify patients who will respond positively to specific treatments can enhance the effectiveness of therapies and reduce healthcare costs. Manufacturers can collaborate with pharmaceutical companies to develop companion diagnostic assays that enhance treatment selection and personalized patient care. This would present numerous opportunities for the growth of this market.
Clinical immunodiagnostics can involve high costs, including the development and production of assays, instruments, and reagents. The high costs associated with immunodiagnostic tests can limit their accessibility and affordability, particularly in resource-constrained settings or regions with limited healthcare budgets. Cost considerations can impact the demand for clinical immunodiagnostics.
Apart from this, clinical immunodiagnostics faces competition from alternative diagnostic technologies, such as molecular diagnostics, imaging techniques, and other non-immunological assays. These alternative technologies may offer advantages in terms of sensitivity, specificity, multiplexing capabilities, or cost-effectiveness in certain applications. The availability of alternative diagnostic options can limit the demand for clinical immunodiagnostics.
The USA occupies 91.1% of the North America market in 2022. Reimbursement policies play an important role in the adoption of medical technologies. In the USA, favorable reimbursement policies for clinical immunodiagnostics testing have supported market growth. Reimbursement coverage by government programs like Medicare and private insurance companies has incentivized healthcare providers to offer clinical immunodiagnostic-based diagnostics.
Germany’s expenditure in clinical immunodiagnostics in 2022 was USD 310.6 Million. Personalized medicine, which involves tailoring medical treatment to individual patients based on their genetic profile, is gaining prominence in this region. Germany, known for its strong healthcare and research infrastructure, is actively participating in personalized medicine initiatives. Clinical immunodiagnostics being essential in identifying specific biomarkers for personalized medicine drives the demand for various kits and reagents in the country.
In 2022, China held a significant share of the East Asia market and is expected to grow at a CAGR of close to 6.4% over the forecast period. Chinese clinical immunodiagnostics manufacturers are increasingly collaborating with international companies, leveraging expertise, technologies, and market access. These collaborations help in technology transfer, product development, and expanding the market reach of clinical immunodiagnostics in China. Also, partnerships with healthcare providers and research institutions contribute to the growth of the clinical immunodiagnostics market in China.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
By product, immunoassay kits & reagents held 67.8% market share in the world in 2022 and are expected to expand rapidly with a CAGR of 5.4% from 2023 to 2033. Immunoassay kits and reagents have a broad range of applications in clinical immunodiagnostics, covering various disease areas, including infectious diseases, autoimmune disorders, oncology, cardiovascular diseases, and endocrinology. Their versatility and adaptability to different analytes make them essential tools for diagnosing and monitoring a diverse set of medical conditions.
The market value of serum sample type was USD 1.7 Billion, representing a sizable 35.4% market share in 2022. Serum samples are readily available and routinely used in clinical practice. Healthcare facilities and laboratories can easily collect serum samples from patients for diagnostic testing, making them a convenient and accessible source of biomaterial for immunodiagnostics.
By application, infectious disease accounted for a prominent share of the global market, with a revenue share of 20.7% in 2022. Infectious diseases are widespread and continue to pose a significant global health burden. The high prevalence of infectious diseases, such as influenza, HIV/AIDS, hepatitis, tuberculosis, and various respiratory infections, drives the demand for diagnostic tests based on immunodiagnostics.
With a 26.1% value share in 2022 and a strong CAGR of 6.4% over the projected period, the hospital has a sizable position in this market. Hospitals cater to a large number of patients with diverse medical conditions. As a result, they have a substantial demand for diagnostic testing, including clinical immunodiagnostics. Hospitals frequently utilize immunodiagnostic tests to aid in the diagnosis and inspection of various diseases.
Collaborations with medical professionals, academic institutions, and IT companies can promote creativity and speed up clinical immunodiagnostics. Also, collaboration in research, development, and commercialization can result in new applications and a larger market. The market for clinical immunodiagnostics is dominated by multiple sizable businesses. The important advances of the major companies in this market are illustrated by the following examples:
Similarly, recent developments related to the companies, manufacturing the clinical immunodiagnostics products have been tracked by the team at Future Market Insights, which are available in the full report.
| Report Attributes | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value, Units for Volume |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, France, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Thailand, Malaysia, Australia, New Zealand, GCC Countries, Türkiye, South Africa and Northern Africa |
| Key Market Segments Covered | Product, Sample Type, Application, End User, and Region |
| Key Companies Profiled | Surmodics, Inc.; MESO SCALE DIAGNOSTICS, LLC.; Abbott; Siemens Healthineers; PerkinElmer Inc.; Becton, Dickinson and Company; Thermo Fisher Scientific Inc.; Zoetis Inc.; Promega Corporation; F. Hoffmann-La Roche; BIOMÉRIEUX SA; Elabscience Biotechnology Inc.; Innovative Research, Inc.; QIAGEN N.V.; Merck KGaA; Bio-Rad Laboratories, Inc.; Creative Diagnostics; Cell Signaling Technology (CST); NEW HORIZONS DIAGNOSTIC CORPORATION; DiaSorin S.p.A.; H.U. Group Holdings Inc; IDEXX Laboratories Inc.; Randox Laboratories Ltd.; Biopanda Reagents Ltd.; Shenzhen Bioeasy Biotechnology Co., Ltd.; Quidel Corporation; Advnt Biotechnologies.; RESPONSE BIOMEDICAL.; Danaher Corporation |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The clinical immunodiagnostics market size is valued at USD 5.0 billion in 2023.
The United States occupied 91.1% of the North American clinical immunodiagnostics market share in 2022.
China’s clinical immunodiagnostics market in East Asia rose at a 6.4% CAGR in 2022.
The immunoassay kits & reagents segment will thrive at a 5.4% CAGR from 2023 to 2033.
The infectious disease segment garnered 20.7% of the clinical immunodiagnostics market’s revenue share in 2022.
| Estimated Size, 2024 | USD 60.4 billion |
|---|---|
| Projected Size, 2034 | USD 136.7 billion |
| Value-based CAGR (2024 to 2034) | 8.5% |
| Expected Market Size (2024E) | USD 635 million |
|---|---|
| Projected Market Value (2034F) | USD 3,131.5 million |
| Value-based CAGR (2024 to 2034) | 17.3% |
| Market Valuation (2023) | USD 4.4 billion |
|---|---|
| Market Valuation (2033) | USD 11.1 billion |
| Market CAGR (2023 to 2033) | 9.7% |
| Expected Market Value (2022) | USD 385.7Million |
|---|---|
| Anticipated Forecast Value (2032) | USD 658.9 Million |
| Projected Growth Rate (2022 to 2032) | 5.5% CAGR |
Explore Life Science & Biotechnology Insights
View Reports
Clinical Immunodiagnostics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
